A citation-based method for searching scientific literature


List of co-cited articles
721 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity





Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
15

Therapeutic potential of venom peptides.
Richard J Lewis, Maria L Garcia. Nat Rev Drug Discov 2003
497
13

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
734
11

Peptide therapeutics from venom: Current status and potential.
Michael W Pennington, Andrzej Czerwinski, Raymond S Norton. Bioorg Med Chem 2018
131
10


The toxicogenomic multiverse: convergent recruitment of proteins into animal venoms.
Bryan G Fry, Kim Roelants, Donald E Champagne, Holger Scheib, Joel D A Tyndall, Glenn F King, Timo J Nevalainen, Janette A Norman, Richard J Lewis, Raymond S Norton,[...]. Annu Rev Genomics Hum Genet 2009
491
9

Complex cocktails: the evolutionary novelty of venoms.
Nicholas R Casewell, Wolfgang Wüster, Freek J Vonk, Robert A Harrison, Bryan G Fry. Trends Ecol Evol 2013
456
9

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
9

From snake venom toxins to therapeutics--cardiovascular examples.
Cho Yeow Koh, R Manjunatha Kini. Toxicon 2012
130
9

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
8

Contulakin-G, an O-glycosylated invertebrate neurotensin.
A G Craig, T Norberg, D Griffin, C Hoeger, M Akhtar, K Schmidt, W Low, J Dykert, E Richelson, V Navarro,[...]. J Biol Chem 1999
152
8

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Jesper Lau, Paw Bloch, Lauge Schäffer, Ingrid Pettersson, Jane Spetzler, Jacob Kofoed, Kjeld Madsen, Lotte Bjerre Knudsen, James McGuire, Dorte Bjerre Steensgaard,[...]. J Med Chem 2015
345
8

Toxins and drug discovery.
Alan L Harvey. Toxicon 2014
114
8

Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a.
Irène R Chassagnon, Claudia A McCarthy, Yanni K-Y Chin, Sandy S Pineda, Angelo Keramidas, Mehdi Mobli, Vi Pham, T Michael De Silva, Joseph W Lynch, Robert E Widdop,[...]. Proc Natl Acad Sci U S A 2017
105
8


Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
950
7

Black mamba venom peptides target acid-sensing ion channels to abolish pain.
Sylvie Diochot, Anne Baron, Miguel Salinas, Dominique Douguet, Sabine Scarzello, Anne-Sophie Dabert-Gay, Delphine Debayle, Valérie Friend, Abdelkrim Alloui, Michel Lazdunski,[...]. Nature 2012
244
7


Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
John B Buse, Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K Shenouda, Cory R Heilmann, Byron J Hoogwerf, Aijun Gao, Marilyn K Boardman, Mark Fineman,[...]. Lancet 2013
347
7

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Kathleen M Dungan, Santiago Tofé Povedano, Thomas Forst, José G González González, Charles Atisso, Whitney Sealls, Jessie L Fahrbach. Lancet 2014
293
7

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Dennis Kim, Leigh MacConell, Dongliang Zhuang, Prajakti A Kothare, Michael Trautmann, Mark Fineman, Kristin Taylor. Diabetes Care 2007
341
7

Development of eptifibatide.
R M Scarborough. Am Heart J 1999
100
7

Specialized insulin is used for chemical warfare by fish-hunting cone snails.
Helena Safavi-Hemami, Joanna Gajewiak, Santhosh Karanth, Samuel D Robinson, Beatrix Ueberheide, Adam D Douglass, Amnon Schlegel, Julita S Imperial, Maren Watkins, Pradip K Bandyopadhyay,[...]. Proc Natl Acad Sci U S A 2015
86
7

A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
5

Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4.
A Thum, K Hupe-Sodmann, R Göke, K Voigt, B Göke, G P McGregor. Exp Clin Endocrinol Diabetes 2002
46
10

Bioactive peptides from lizard venoms.
J P Raufman. Regul Pept 1996
58
8

Early evolution of the venom system in lizards and snakes.
Bryan G Fry, Nicolas Vidal, Janette A Norman, Freek J Vonk, Holger Scheib, S F Ryan Ramjan, Sanjaya Kuruppu, Kim Fung, S Blair Hedges, Michael K Richardson,[...]. Nature 2006
335
5

Peptide neurotoxins from fish-hunting cone snails.
B M Olivera, W R Gray, R Zeikus, J M McIntosh, J Varga, J Rivier, V de Santos, L J Cruz. Science 1985
629
5

Orthosteric binding of ρ-Da1a, a natural peptide of snake venom interacting selectively with the α1A-adrenoceptor.
Arhamatoulaye Maïga, Jon Merlin, Elodie Marcon, Céline Rouget, Maud Larregola, Bernard Gilquin, Carole Fruchart-Gaillard, Evelyne Lajeunesse, Charles Marchetti, Alain Lorphelin,[...]. PLoS One 2013
8
62

Identification, structural and pharmacological characterization of τ-CnVA, a conopeptide that selectively interacts with somatostatin sst3 receptor.
C Petrel, H G Hocking, M Reynaud, G Upert, Ph Favreau, D Biass, M Paolini-Bertrand, S Peigneur, J Tytgat, N Gilles,[...]. Biochem Pharmacol 2013
26
19


Conopressin-T from Conus tulipa reveals an antagonist switch in vasopressin-like peptides.
Sébastien Dutertre, Daniel Croker, Norelle L Daly, Asa Andersson, Markus Muttenthaler, Natalie G Lumsden, David J Craik, Paul F Alewood, Gilles Guillon, Richard J Lewis. J Biol Chem 2008
60
8


Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
911
5

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Michael Nauck, Anders Frid, Kjeld Hermansen, Nalini S Shah, Tsvetalina Tankova, Ismail H Mitha, Milan Zdravkovic, Maria Düring, David R Matthews. Diabetes Care 2009
794
5

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Thomas Blevins, John Pullman, Jaret Malloy, Ping Yan, Kristin Taylor, Christine Schulteis, Michael Trautmann, Lisa Porter. J Clin Endocrinol Metab 2011
306
5

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Alan Garber, Robert Henry, Robert Ratner, Pedro A Garcia-Hernandez, Hiromi Rodriguez-Pattzi, Israel Olvera-Alvarez, Paula M Hale, Milan Zdravkovic, Bruce Bode. Lancet 2009
776
5



Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
David Russell-Jones, Robert M Cuddihy, Markolf Hanefeld, Ajay Kumar, Jose G González, Melanie Chan, Anne M Wolka, Marilyn K Boardman. Diabetes Care 2012
248
5

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
Guillermo Umpierrez, Santiago Tofé Povedano, Federico Pérez Manghi, Linda Shurzinske, Valeria Pechtner. Diabetes Care 2014
196
5

ConoServer: updated content, knowledge, and discovery tools in the conopeptide database.
Quentin Kaas, Rilei Yu, Ai-Hua Jin, Sébastien Dutertre, David J Craik. Nucleic Acids Res 2012
211
5

The engineering of an orally active conotoxin for the treatment of neuropathic pain.
Richard J Clark, Jonas Jensen, Simon T Nevin, Brid P Callaghan, David J Adams, David J Craik. Angew Chem Int Ed Engl 2010
213
5

Evolution of separate predation- and defence-evoked venoms in carnivorous cone snails.
Sébastien Dutertre, Ai-Hua Jin, Irina Vetter, Brett Hamilton, Kartik Sunagar, Vincent Lavergne, Valentin Dutertre, Bryan G Fry, Agostinho Antunes, Deon J Venter,[...]. Nat Commun 2014
177
5


The first venomous crustacean revealed by transcriptomics and functional morphology: remipede venom glands express a unique toxin cocktail dominated by enzymes and a neurotoxin.
Björn M von Reumont, Alexander Blanke, Sandy Richter, Fernando Alvarez, Christoph Bleidorn, Ronald A Jenner. Mol Biol Evol 2014
58
8

Design of angiotensin converting enzyme inhibitors.
D W Cushman, M A Ondetti. Nat Med 1999
130
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.